Drug intelligence / Profile preview

KJ14002

Development stage: Preclinical
Lead developer: Kukje Pharm
Modality: Small Molecules
Administration: Ophthalmic

Overview

KJ14002 (also known as TFC-003) is a triple-combination small molecule ophthalmic therapy under development by Kukje Pharm for the treatment of glaucoma and other ophthalmic diseases. Classified as an improved/modified new drug (IMD) in South Korea, the candidate aims to enhance therapeutic efficacy in reducing intraocular pressure (IOP) and improve patient compliance by combining three active pharmaceutical ingredients into a single formulation. The program is currently in the discovery research stage, focusing on optimizing the synergistic effects of its components for the management of ocular hypertension.

Beyond the preview

Go deeper on KJ14002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ14002.

Explore the full profile